Timing the first postoperative dose of anticoagulants: Lessons learned from clinical trials

Chest

Volumn 148, Issue 3, 2015, Pages 587-595

  Paikin, Jeremy S ^a   Hirsh, Jack ^a   Chan, Noel C ^b   Ginsberg, Jeffrey S ^a   Weitz, Jeffrey I ^a,c   Eikelboom, John W ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; ENOXAPARIN; RIVAROXABAN; WARFARIN; ANTITHROMBIN;

BLEEDING; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; REVIEW; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATIONS; TIME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; TIME FACTORS;

EID: 84941660695     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2710     Document Type: Note

References (35)

1. Eriksson BI, Dahl OE, Büller HR, et al; BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost. 2005; 3 ( 1): 103-111.
2. Turpie AG, Fisher WD, Bauer KA, et al; OdiXa-Knee Study Group. BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients aft er total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005; 3 ( 11): 2479-2486.
3. Eriksson BI, Borris L, Dahl OE, et al; ODIXa-HIP Study Investigators. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism aft er total hip replacement. J Thromb Haemost. 2006; 4 ( 1): 121-128.
4. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The effi cacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007; 5 ( 12): 2368-2375.
5. Eriksson BI, Borris LC, Dahl OE, et al; ODIXa-HIP Study Investigators. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis aft er total hip replacement. Circulation. 2006; 114 ( 22): 2374-2381.
6. Bergqvist D, Burmark US, Frisell J, et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986; 73 ( 3): 204-208.
7. Bergqvist D, Mätzsch T, Burmark US, et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg. 1988; 75 ( 9): 888-891.
8. Turpie AG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986; 315 ( 15): 925-929.
9. Hull RD, Pineo GF, Francis C, et al; The North American Fragmin Trial Investigators. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison. Arch Intern Med. 2000; 160 ( 14): 2199-2207.
10. Colwell CW Jr, Kwong LM, Turpie AG, Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty. 2006; 21 ( 1): 36-45.
11. Gallus AS, Hirsh J, Tutle RJ, et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med. 1973; 288 ( 11): 545-551.
12. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 1975; 2 ( 7924): 45-51.
13. Clagett GP, Salzman EW. Prevention of venous thromboembolism in surgical patients. N Engl J Med. 1974; 290 ( 2): 93-96.
14. Gruber UF, Saldeen T, Brokop T, et al. Incidences of fatal postoperative pulmonary embolism aft er prophylaxis with dextran 70 and low-dose heparin: An international multicentre study. BMJ. 1980; 280 ( 6207): 69-72.
15. Coventry MB, Nolan DR, Beckenbaugh RD. "Delayed" prophylactic anticoagulation: A study of results and complications in 2, 012 total hip arthroplasties. J Bone Joint Surg Am. 1973; 55 ( 7): 1487-1492.
16. Spiro TE, Johnson GJ, Christie MJ, et al; Enoxaparin Clinical Trial Group. Effi cacy and safety of enoxaparin to prevent deep venous thrombosis aft er hip replacement surgery. Ann Intern Med. 1994; 121 ( 2): 81-89.
17. Colwell CW Jr, Spiro TE, Trowbridge AA, et al; Enoxaparin Clinical Trial Group. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis aft er elective hip replacement. A clinical trial comparing effi cacy and safety. J Bone Joint Surg Am. 1994; 76 ( 1): 3-14.
18. Eriksson BI, Bauer KA, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism aft er hip-fracture surgery. N Engl J Med. 2001; 345 ( 18): 1298-1304.
19. Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison. Lancet. 2002; 359 ( 9319): 1715-1720.
20. Bauer KA, Eriksson BI, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism aft er elective major knee surgery. N Engl J Med. 2001; 345 ( 18): 1305-1310.
21. Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial. Lancet. 2002; 359 ( 9319): 1721-1726.
22. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized doubleblind studies. Arch Intern Med. 2002; 162 ( 16): 1833-1840.
23. Turpie AG, Bauer K, Eriksson B. Eff ect on effi cacy and safety of the timing of the fi rst administration of fondaparinux in the prophylaxis of venous thromboembolism following major orthopedic surgery. Presented at: Seventh Annual Meeting of the European Hematology Association; 2002; Florence, Italy.
24. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis aft er hip arthroplasty. N Engl J Med. 2008; 358 ( 26): 2765-2775.
25. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism aft er total hip arthroplasty: A double-blind, randomised controlled trial. Lancet. 2008; 372 ( 9632): 31-39.
26. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis aft er total knee arthroplasty. N Engl J Med. 2008; 358 ( 26): 2776-2786.
27. Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis aft er total knee arthroplasty (RECORD4): A randomised trial. Lancet. 2009; 373 ( 9676): 1673-1680.
28. Lassen MR, Gallus AS, Pineo GF, Raskob GE. Late breaking clinical trial: The ADVANCE-2 Study: A randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis aft er total knee replacement. J Thromb Haemost. 2009;LB-MO-005.
29. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis aft er knee replacement (ADVANCE-2): A randomised double-blind trial. Lancet. 2010; 375 ( 9717): 807-815.
30. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis aft er hip replacement. N Engl J Med. 2010; 363 ( 26): 2487-2498.
31. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004; 2 ( 9): 1573-1580.
32. Eriksson BI, Dahl OE, Rosencher N, et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism aft er total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost. 2007; 5 ( 11): 2178-2185.
33. Eriksson BI, Dahl OE, Rosencher N, et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism aft er total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370 ( 9591): 949-956.
34. Ginsberg JS, Davidson BL, Comp PC, et al; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism aft er knee arthroplasty surgery. J Arthroplasty. 2009; 24 ( 1): 1-9.
35. Eriksson BI, Dahl OE, Huo MH, et al; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis aft er primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105 ( 4): 721-729.